ATE252316T1 - Injizierbare zusammensetzungen - Google Patents

Injizierbare zusammensetzungen

Info

Publication number: ATE252316T1
Authority: AT; Austria
Prior art keywords: warm; blooded animals; injectable compositions; diseases; moxidecting
Prior art date: 1996-06-05

Application number

AT97924403T

Other languages

English (en)

Inventor

Colin Manson Harvey

Original Assignee

Ashmont Holdings Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-06-05

Filing date

1997-06-05

Publication date

2003-11-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26651622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE252316(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-06-05 Priority claimed from NZ286752A external-priority patent/NZ286752A/en

1997-06-05 Application filed by Ashmont Holdings Ltd filed Critical Ashmont Holdings Ltd

2003-11-15 Application granted granted Critical

2003-11-15 Publication of ATE252316T1 publication Critical patent/ATE252316T1/de

Links

239000007972 injectable composition Substances 0.000 title abstract 2
239000005660 Abamectin Substances 0.000 abstract 2
241001465754 Metazoa Species 0.000 abstract 2
AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 abstract 1
IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 abstract 1
SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 abstract 1
208000030852 Parasitic disease Diseases 0.000 abstract 1
229950008167 abamectin Drugs 0.000 abstract 1
239000002671 adjuvant Substances 0.000 abstract 1
239000000427 antigen Substances 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 abstract 1
230000001580 bacterial effect Effects 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
QLFZZSKTJWDQOS-YDBLARSUSA-N doramectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C3CCCCC3)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C QLFZZSKTJWDQOS-YDBLARSUSA-N 0.000 abstract 1
229960003997 doramectin Drugs 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
229960002418 ivermectin Drugs 0.000 abstract 1
239000007788 liquid Substances 0.000 abstract 1
FXWHFKOXMBTCMP-WMEDONTMSA-N milbemycin Natural products COC1C2OCC3=C/C=C/C(C)CC(=CCC4CC(CC5(O4)OC(C)C(C)C(OC(=O)C(C)CC(C)C)C5O)OC(=O)C(C=C1C)C23O)C FXWHFKOXMBTCMP-WMEDONTMSA-N 0.000 abstract 1
230000003071 parasitic effect Effects 0.000 abstract 1
230000003612 virological effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Microbiology (AREA)
Mycology (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT97924403T 1996-06-05 1997-06-05 Injizierbare zusammensetzungen ATE252316T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
NZ286752A NZ286752A (en)	1996-06-05	1996-06-05	Stable injectable composition of endecticides
NZ29909396		1996-07-30
PCT/NZ1997/000073 WO1997046204A2 (en)	1996-06-05	1997-06-05	Injectable compositions

Publications (1)

Publication Number	Publication Date
ATE252316T1 true ATE252316T1 (de)	2003-11-15

Family

ID=26651622

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97924403T ATE252316T1 (de)	1996-06-05	1997-06-05	Injizierbare zusammensetzungen

Country Status (7)

Country	Link
US (2)	US6214367B1 (de)
EP (1)	EP0928136B1 (de)
AT (1)	ATE252316T1 (de)
AU (1)	AU728221B2 (de)
CA (1)	CA2259469A1 (de)
DE (1)	DE69725745D1 (de)
WO (1)	WO1997046204A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ280086A (en) *	1995-09-25	1997-08-22	Ashmont Holdings Ltd	Injectable veterinary abamectin composition; also comprises a vegetable oil and an alcohol having 4 or more carbon atoms
US6458373B1 (en)	1997-01-07	2002-10-01	Sonus Pharmaceuticals, Inc.	Emulsion vehicle for poorly soluble drugs
US20040208926A1 (en) *	1997-07-01	2004-10-21	Pfizer Inc	Solubilized sertraline compositions
US6524592B2 (en)	1997-10-17	2003-02-25	American Home Products Corporation	Veterinary vaccines
US7030155B2 (en)	1998-06-05	2006-04-18	Sonus Pharmaceuticals, Inc.	Emulsion vehicle for poorly soluble drugs
NO312056B1 (no) *	1998-06-09	2002-03-11	Alpharma As Aquatic Animal Hea	Anvendelse av preparater til forebygging og behandling av parasitter hos fisk
AU781682B2 (en) *	2000-03-20	2005-06-09	Zoetis Services Llc	Sustained-release compositions for parenteral administration
US6627613B2 (en)	2001-07-23	2003-09-30	Michael A. Strobel	Application of water and organic solvent soluble ivermectin for topical and oral use
US20050009762A1 (en) *	2003-06-06	2005-01-13	Strobel Michael Albert	Application of water and organic solvent soluble ivermectin for topical and oral use
KR100600406B1 (ko) *	2002-07-22	2006-07-14	주식회사 엘지생명과학	주사용 이버멕틴 조성물 및 그 제조방법
UY27412A1 (es) *	2002-08-12	2003-06-30	Carlson Internat Inc	Un nuevo producto para el combate de garrapatas y el proceso para la prepaacinn.
US7731947B2 (en)	2003-11-17	2010-06-08	Intarcia Therapeutics, Inc.	Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US7396819B2 (en) *	2003-08-08	2008-07-08	Virbac Corporation	Anthelmintic formulations
WO2005094210A2 (en) *	2004-03-12	2005-10-13	The Hartz Mountain Corporation	Multi-action anthelmintic formulations
WO2006083761A2 (en)	2005-02-03	2006-08-10	Alza Corporation	Solvent/polymer solutions as suspension vehicles
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
CN100459864C (zh) *	2006-05-19	2009-02-11	东北农业大学	多拉菌素、塞拉菌素水乳剂及其制备方法
KR101106510B1 (ko)	2006-05-30	2012-01-20	인타르시아 세라퓨틱스 인코포레이티드	투피스, 내부채널 삼투압 전달 시스템 유동 조절기
EP2359808B1 (de)	2006-08-09	2013-05-22	Intarcia Therapeutics, Inc	Osmotisches Verabreichungssystem mit Kolbenanordnung
WO2008133908A2 (en)	2007-04-23	2008-11-06	Intarcia Therapeutics, Inc.	Suspension formulations of insulinotropic peptides and uses thereof
CN106310293A (zh)	2007-09-27	2017-01-11	免疫疫苗技术有限公司	在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
US20100209452A1 (en) *	2007-10-03	2010-08-19	Immunovaccine Technologies, Inc	Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
CA2726861C (en)	2008-02-13	2014-05-27	Intarcia Therapeutics, Inc.	Devices, formulations, and methods for delivery of multiple beneficial agents
WO2009146523A1 (en) *	2008-06-05	2009-12-10	Immunovaccine Technologies Inc.	Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
DK2396006T3 (da) *	2009-02-16	2013-02-11	Ah Usa 42 Llc	Doramectinformulering med høj dosis
US8313752B2 (en) *	2009-04-14	2012-11-20	Merial Limited	Macrocyclic lactone combination compositions, vaccines and methods for producing same
RU2547990C2 (ru)	2009-09-28	2015-04-10	Интарсия Терапьютикс, Инк.	Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
EP2485725A2 (de) *	2009-10-07	2012-08-15	Wyeth LLC	Zusammensetzungen mit adjuvanzien, makroliden und proteinösen antigenen sowie verwendungsverfahren dafür
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
NZ594610A (en) *	2011-08-16	2013-03-28	Virbac New Zealand Ltd	Injectable Anthelmintic Formulations cotaining levamisole and one or more macrocyclic lactones for controlling internal parasites in ruminants
CN113876945A (zh)	2011-10-06	2022-01-04	免疫疫苗技术有限公司	包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
RU2730996C2 (ru)	2015-06-03	2020-08-26	Интарсия Терапьютикс, Инк.	Системы установки и извлечения имплантата
KR102574993B1 (ko)	2016-05-16	2023-09-06	인타르시아 세라퓨틱스 인코포레이티드	글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
JP7286542B2 (ja)	2017-01-03	2023-06-05	インターシアセラピューティクス，インコーポレイティド	Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
US11077134B1 (en)	2020-11-10	2021-08-03	Mountain Valley Md Inc	Water dissolvable macrocyclic lactone cyclodextrin complexes
US11638714B2 (en)	2020-11-10	2023-05-02	Mountain Valley Md Inc	Water dissolvable macrocyclic lactone cyclodextrin complexes
CN114642632A (zh) *	2022-02-25	2022-06-21	河北科技大学	一种莫西克汀注射液及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1143545A (en)	1965-03-25	1969-02-26	Wellcome Found	Injectable vaccine emulsions
GB1171125A (en)	1966-06-08	1969-11-19	Glaxo Lab Ltd	Improvements in or relating to Injectable Preparations
SE434277B (sv)	1976-04-19	1984-07-16	Merck & Co Inc	Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis
NZ186851A (en)	1977-04-11	1984-12-14	Merck & Co Inc	Glycosyloxy derivatives of milbemycin and parasiticidal compositions
US4093629A (en)	1977-04-11	1978-06-06	Merck & Co., Inc.	Derivatives of antibiotic substance milbemycin and processes therefor
SU627611A1 (ru)	1977-09-30	1980-02-05	В.П. Землякова	Вакцинный препарат в.п. земл ковой против клостридиозов животных и птиц
US4199569A (en)	1977-10-03	1980-04-22	Merck & Co., Inc.	Selective hydrogenation products of C-076 compounds and derivatives thereof
NZ188459A (en)	1977-10-03	1982-09-07	Merck & Co Inc	Derivatives of c-076 compounds and pesticidal compositions
PH15982A (en)	1977-10-03	1983-05-18	Merck & Co Inc	Selective hydrogenation producta of c-076 compounds and derivatives thereof
NZ191413A (en) *	1978-09-11	1981-10-19	Ici Australia Ltd	Anthelmintic and anticlostridial composition containing a tetramisole salt
NZ193807A (en)	1979-05-31	1983-03-15	Ici Tasman Ltd	Improving the response of ruminants to clostridial vaccine by administering tetramisole or levamisole
JPS57139012A (en)	1981-02-23	1982-08-27	Sankyo Co Ltd	Anthelmintic composition
US4606918A (en)	1983-08-22	1986-08-19	Syntex (U.S.A.) Inc.	Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4781920A (en)	1984-11-13	1988-11-01	American Cyanamid Company	Anthelmintic paste compositions containing resinates of d1-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole
US4784845A (en)	1985-09-16	1988-11-15	American Cyanamid Company	Emulsion compostions for the parenteral administration of sparingly water soluble ionizable hydrophobic drugs
EP0393890B1 (de) *	1989-04-11	1992-08-12	Pfizer Limited	Injizierbare Arzneizubereitungen, die 25-Cyclohexylavermectin B1 enthalten
US5733566A (en) *	1990-05-15	1998-03-31	Alkermes Controlled Therapeutics Inc. Ii	Controlled release of antiparasitic agents in animals
US5639876A (en) *	1991-02-12	1997-06-17	Heska Corporation	Nucleic acid molecules encoding novel parasitic helminth proteins
US5262400A (en)	1991-06-20	1993-11-16	Merck & Co., Inc.	4α-substituted avermectin derivatives
PT697814E (pt)	1993-05-10	2003-11-28	Merck & Co Inc	Formulacoes para verter que contem material polimerico glicois e gliceridos
US5550153A (en) *	1994-11-14	1996-08-27	Kerz; Phillip D.	Method for treating heartworm-infected canines
PT750907E (pt) *	1995-06-30	2002-08-30	American Cyanamid Co	Formulacoes de vacinas estaveis para administracao parenterica metodo para a sua utilizacao e processo para a sua preparacao

1997
- 1997-06-05 CA CA002259469A patent/CA2259469A1/en not_active Abandoned
- 1997-06-05 AU AU29829/97A patent/AU728221B2/en not_active Withdrawn - After Issue
- 1997-06-05 EP EP97924403A patent/EP0928136B1/de not_active Revoked
- 1997-06-05 DE DE69725745T patent/DE69725745D1/de not_active Expired - Lifetime
- 1997-06-05 US US09/214,260 patent/US6214367B1/en not_active Expired - Lifetime
- 1997-06-05 AT AT97924403T patent/ATE252316T1/de not_active IP Right Cessation
- 1997-06-05 WO PCT/NZ1997/000073 patent/WO1997046204A2/en not_active Ceased
2001
- 2001-02-21 US US09/788,572 patent/US6663879B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AU2982997A (en)	1998-01-05
WO1997046204A2 (en)	1997-12-11
DE69725745D1 (de)	2003-11-27
AU728221B2 (en)	2001-01-04
US6214367B1 (en)	2001-04-10
US20010014336A1 (en)	2001-08-16
EP0928136B1 (de)	2003-10-22
WO1997046204A3 (en)	1998-03-12
EP0928136A4 (de)	2001-11-14
EP0928136A2 (de)	1999-07-14
US6663879B2 (en)	2003-12-16
CA2259469A1 (en)	1997-12-11

Legal Events

Date	Code	Title	Description
2004-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69725745D1 (de)	2003-11-27	Injizierbare zusammensetzungen
BRPI9809791B8 (pt)	2021-05-25	compostos imuno efetores de fosfato de aminoalquil glucosamina e composições compreendendo os mesmos
LU91928I2 (fr)	2012-03-09	Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
NZ336344A (en)	2001-03-30	Endoparasiticidal and ectoparasiticidal compositions comprising an avermectin, ivermectin or milemycin with antagonists or agonists of nicotinergic acetylcholine receptors
AU560864B2 (en)	1987-04-16	Pharmaceutical parenteral compositions of an avermectin and propylene glycol
UY24268A1 (es)	2001-10-25	Composiciones estables de vacunas para la administración parenteral, método para su utilización
TR200003513T2 (tr)	2001-06-21	Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları
DK1121135T3 (da)	2009-03-23	Præparater af beta-glucaner og specifikke immunglobuliner
EP1314431A3 (de)	2003-06-18	Newcastle-Krankheitsvirus zur therapeutischen Verwendungen
PT1157041E (pt)	2005-10-31	Anticorpos para terapia e diagnostico de cancro
IL94167A (en)	1997-02-18	Immunoconjugate targeting 15A8 or ZME-018 antigens and comprising TNF or interleukin-1
TR199900083T2 (xx)	1999-04-21	Klaritromisinin kristal bi�imi I.
BR0010220A (pt)	2002-05-14	Compostos de pirimidinona
AU2275397A (en)	1997-09-02	Troponin subunits and fragments useful as angiogenesis inhibitors
CY1107789T1 (el)	2013-06-19	Ανθελμινθικαι συνθεσεις περιεχουσαι συνδυασμους αβερμεκτινων ή μιλβεμυκινων μετα δις-αρυλο ενωσεων
BR0215392A (pt)	2004-12-07	Composições farmacêuticas compreendendo um inibidor de fosfodiesterase multifuncional e um inibidor de absorção de adenosina, bem como uso das mesmas
DK1051180T3 (da)	2002-08-19	Phospholipider med antimikrobiel aktivitet i nærværelse af antimikrobielle midler
PT1272199E (pt)	2005-05-31	Terapias de combinacao com actividade de lesao vascular
AU2005099A (en)	1999-07-12	Methods and compositions for the treatment and prevention of (staphylococcus aureus) infections
ES2157886T3 (es)	2001-09-01	Composiciones tensioactivas y procedimientos.
PT1085884E (pt)	2005-07-29	Combinacao de compostos seleniferos com gemcitabina ou mitomicina c
BR9900114A (pt)	2000-05-02	Composições de ciclodextrina.
AU3439799A (en)	1999-11-23	Immunization against and treatment for infection by (h.pylori)
PA8486601A1 (es)	2000-09-29	Formulaciones antiparasitos
WO2002102307B1 (en)	2004-05-21	Nucleoside vaccine adjuvants